¹²³I-Meta-iodobenzylguanidine Sympathetic Imaging: Standardization and Application to Neurological Diseases / 전남의대학술지
Chonnam Medical Journal
; : 145-150, 2016.
Article
in En
| WPRIM
| ID: wpr-788354
Responsible library:
WPRO
ABSTRACT
¹²³I-meta-iodobenzylguanidine (MIBG) has become widely applied in Japan since its introduction to clinical cardiology and neurology practice in the 1990s. Neurological studies found decreased cardiac uptake of ¹²³I-MIBG in Lewy-body diseases including Parkinson's disease and dementia with Lewy bodies. Thus, cardiac MIBG uptake is now considered a biomarker of Lewy body diseases. Although scintigraphic images of ¹²³I-MIBG can be visually interpreted, an average count ratio of heart-to-mediastinum (H/M) has commonly served as a semi-quantitative marker of sympathetic activity. Since H/M ratios significantly vary according to acquisition and processing conditions, quality control should be appropriate, and quantitation should be standardized. The threshold H/M ratio for differentiating Lewy-body disease is 2.0-2.1, and was based on standardized H/M ratios to comparable values of medium-energy collimators. Parkinson's disease can be separated from various types of parkinsonian syndromes using cardiac ¹²³I-MIBG, whereas activity is decreased on images of Lewy-body diseases using both ¹²³I-ioflupane for the striatum and ¹²³I-MIBG. Despite being a simple index, the H/M ratio of ¹²³I-MIBG uptake is reproducible and can serve as an effective tool to support a diagnosis of Lewy-body diseases in neurological practice.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Parkinson Disease
/
Quality Control
/
Cardiology
/
Lewy Bodies
/
3-Iodobenzylguanidine
/
Parkinsonian Disorders
/
Lewy Body Disease
/
Dementia
/
Diagnosis
/
Japan
Type of study:
Diagnostic_studies
Country/Region as subject:
Asia
Language:
En
Journal:
Chonnam Medical Journal
Year:
2016
Type:
Article